A suramin derivative induces enterocyte-like differentiation of human colon cancer cells without lysosomal storage disorder.
Suramin is a polysulfonated naphthylurea currently investigated for the treatment of advanced malignancy. We have previously reported that suramin was a potent inducer of the differentiation of the human colic adenocarcinoma cell clone HT29-D4 (Fantini et al., J Biol Chem, 1989; 264: 10282-10286). In this report, we show that chronic suramin treatment of these cells is associated with a lysosomal storage disease. We have tested five suramin-related compounds for their ability to induce HT29-D4 differentiation and we looked at their action on the lysosomal apparatus. We conclude that one of the derivatives used is a more potent differentiation inducer than suramin, while it does not elicit any perturbation of the lysosomal system.
Baghdiguian
S
S
Institut de Chimie Biologique, Université d'Aix-Marseille I, France.
Nickel
P
P
Marvaldi
J
J
Fantini
J
J
D002454:Cell Differentiation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000648:ultrastructure; D006801:Humans; D016464:Lysosomal Storage Diseases / Q000473:pathology*; D008247:Lysosomes / Q000187:drug effects; D013498:Suramin / Q000031:analogs & derivatives* / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D013498:Suramin